Your Dentist Now Asks About GLP-1 Medications. Here Is Why.

If you take a GLP-1 medication, your dentist should know about it.

This is no longer just a general suggestion to mention all your medications. The American Dental Association's Council on Dental Practice approved changes to the Medical/Dental Health History Form in January 2026, and the updated forms became available in March. The revision added GLP-1 medications to the current medication list and a mental health prompt to the general symptoms section. These were the first changes to the forms since 2021 [1].

So the question is now printed on the paperwork. That makes it worth understanding what the question is for.

Telling your dentist that you take a GLP-1 does not mean every dental appointment needs to change.

The sources reviewed here do not establish a routine rule requiring patients to interrupt GLP-1 therapy before an examination, a cleaning, a filling, a dental X-ray, or other ordinary dental care. The picture changes when a procedure involves general anesthesia or deep sedation, because current FDA prescribing information for Wegovy and Mounjaro states that these medicines delay gastric emptying and carries warnings about pulmonary aspiration during such procedures [3] [4].

The practical answer is simple. Tell your dentist what you are taking. Do not assume that means you need to stop it.

Why the health history matters

A health history is part of clinical care, not paperwork to get through before the appointment.

The ADA describes maintaining a complete and accurate medical and dental health history as essential before diagnosing or treating any patient. It notes that a complete history can reveal conditions or medications that affect treatment decisions, and can identify medications that may interact with anesthetics or influence postoperative care [1].

The ADA also sets out how often that history should be refreshed. Active patients of record should review and update their history at every visit, and all patients should complete a new health history form every two years. Discussions about health or medication changes should be documented, including the date [1].

For a GLP-1 patient, that means your dental team should know if you have started one since your last visit, switched to a different medication, increased your dose, or developed new symptoms while taking it.

The reason for asking is not that a GLP-1 automatically causes a dental problem. It is that the medication may become relevant depending on what procedure is planned and what symptoms you are having.

That distinction matters. Disclosure is not the same as automatically changing treatment.

Routine dentistry is not the same as sedation

There is a significant difference between telling your dentist about a medication and being told to stop that medication before treatment.

The ADA change establishes that GLP-1 medications belong in your current medication history [1]. It is a health history question, not clinical guidance about withholding anything.

The procedural concern in the current evidence relates to gastric emptying and to procedures involving general anesthesia or deep sedation [2] [3] [4]. Most dental visits involve neither.

This distinction is worth being clear about, because advice on GLP-1 drugs and surgery has changed over time. Someone searching online may still find instructions saying that everyone on a weekly GLP-1 should stop it for seven days before any procedure. Current multi-society guidance is more individualized than that [2].

For an ordinary dental visit, your role is to provide an accurate medication history. For a procedure involving general anesthesia or deep sedation, that history may become part of the procedural risk assessment.

Why sedation changes the calculation

The concern begins with the stomach rather than the teeth.

Current FDA prescribing information for Wegovy states that Wegovy delays gastric emptying. The current Mounjaro prescribing information says the same for tirzepatide [3] [4].

Both labels carry a warning about pulmonary aspiration during general anesthesia or deep sedation. They describe rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists who underwent procedures requiring general anesthesia or deep sedation and had residual gastric contents despite reported adherence to fasting instructions [3] [4].

That wording needs care.

It does not mean aspiration is expected in everyone taking a GLP-1. The labels describe rare postmarketing reports and state that available data are insufficient to determine whether modifying fasting recommendations or temporarily discontinuing the medication would reduce retained gastric contents [3] [4].

What the labels do say clearly is that patients should inform their healthcare providers before any planned surgery or procedure [3] [4].

Current multi-society perioperative guidance takes the same approach. It identifies delayed gastric emptying and residual gastric contents as a perioperative concern and recommends individual risk assessment rather than assuming identical risk for every patient [2].

Should you stop your GLP-1 before dental surgery?

Not automatically.

The current multi-society guidance says GLP-1 therapy may be continued in patients who do not have elevated risk of delayed gastric emptying and aspiration [2].

It identifies factors that raise concern, including being in the dose escalation phase rather than stable maintenance dosing, taking a higher dose, weekly rather than daily dosing, gastrointestinal symptoms such as nausea or vomiting, and other conditions that can slow gastric emptying [2].

When those factors are present, the answer is still not simply to stop the drug. The guidance says decisions should weigh procedural risk against the consequences of withholding treatment, through shared decision-making among the patient, the procedural team, the anesthesia team, and the prescribing clinician [2].

Where withholding is judged appropriate, the guidance discusses the earlier anesthesiology intervals of holding a daily formulation on the day of the procedure and a weekly formulation for one week, while noting that the optimal withholding duration is not established [2].

That is a different thing from telling every patient on a weekly GLP-1 to stop for seven days.

For patients where delayed gastric emptying is a concern, the guidance also describes options including a liquid diet for at least 24 hours before the procedure, point-of-care gastric ultrasound where available, modification of the anesthesia plan, or postponement [2].

These are clinical decisions. Do not stop a prescribed GLP-1 on your own because a dental procedure is scheduled. Tell the clinical team what you take and let them decide whether anything needs to change.

Tell your dentist about nausea, vomiting, or reflux

There is a second reason the conversation matters, and it applies even when no sedation is involved.

Gastrointestinal symptoms are well documented with these medicines. The current Wegovy prescribing information lists nausea, vomiting, and gastroesophageal reflux disease among the most common adverse reactions, meaning those occurring in at least 5 in 100 patients in the trial program [3].

Those symptoms matter to a dentist because stomach acid reaching the mouth can affect teeth.

This connection does not depend on GLP-1 therapy at all. It has been studied on its own.

In a study of 249 Icelandic individuals referred for assessment, Holbrook and colleagues examined the relationship between gastric reflux and tooth erosion. Participants received a detailed medical history, clinical oral examination, and salivary analysis, and reflux was assessed in 91 of them by gastroscopy, esophageal manometry, and 24-hour esophageal pH monitoring. The authors concluded that gastric reflux was a significant causative factor in tooth erosion [5]. This was a referred sample rather than a general population, so it describes a relationship rather than a population risk.

Vomiting provides a second route for gastric contents to reach the teeth. Of 72 patients referred from eating disorder clinics in Norway, Uhlen and colleagues studied 66 who were experiencing or had experienced self-induced vomiting. Dental erosion was found in 46 of them, or about 70 percent [6].

That study needs an important caveat before anyone maps it onto GLP-1 therapy. The mean duration of self-induced vomiting in that group was 10.6 years, with a range from 3 to 32 years [6]. This is sustained gastric exposure over a decade, not the intermittent nausea some patients experience during dose escalation. The figure cannot be converted into an erosion risk estimate for people taking GLP-1 medications.

What it does establish is that repeated vomiting and gastric acid exposure are associated with substantial erosive tooth damage.

That allows a careful distinction. The evidence does not support saying that GLP-1 drugs erode your teeth. What it supports is narrower. Some GLP-1 medicines are associated with vomiting or reflux in some patients, and repeated reflux and vomiting are independently associated with dental erosion [3] [5] [6].

That is an indirect pathway, not proof of direct toxicity from the medication to the tooth.

If you are having repeated vomiting or reflux while taking a GLP-1, tell both the clinician managing those symptoms and your dentist.

What about dry mouth?

Here the evidence becomes much thinner.

A 2023 case series reported dry mouth and reduced salivary flow in three patients taking semaglutide for weight loss [7].

Three cases cannot tell you how common the problem is. They cannot establish causation, and they cannot establish dry mouth as an effect of the entire GLP-1 category.

The evidence reviewed here does not establish that dry mouth is a predictable class-wide effect of GLP-1 therapy [7].

If you personally develop persistent dry mouth after starting or changing a medication, the symptom is still relevant to your dental care. Reduced saliva raises cavity risk through mechanisms that are well understood and do not depend on any of this. Tell your dentist, and let the cause be evaluated rather than assumed.

What to tell your dental team

You do not need to understand the anesthesia literature before your appointment. You need to give the team accurate information.

Be prepared to say:

• The medication you take, by name.
• Your current dose.
• Whether your dose is currently being increased.
• Whether you are having nausea, vomiting, reflux, abdominal pain, indigestion, constipation, or other significant gastrointestinal symptoms.
• Whether a planned procedure will involve general anesthesia or deep sedation.

If your medication changes between appointments, update the dental office rather than assuming the original history still stands [1].

And if a procedure involving anesthesia is coming up, do not change the medication schedule on your own.

Five things not to assume

My dentist does not need to know because another doctor prescribed it

The ADA added GLP-1 medications to its patient health history forms in 2026 specifically so this comes up in the dental setting [1].

I need to stop my GLP-1 before every dental appointment

The sources reviewed do not establish any routine rule requiring interruption before ordinary dental care. Where delayed gastric emptying and aspiration are relevant, current guidance uses individualized risk assessment [2].

Everyone on a weekly GLP-1 must stop it for seven days

That is not what current multi-society guidance says. Patients without elevated risk may continue therapy. Where withholding is clinically indicated, the guidance discusses the older day-of-procedure and one-week intervals while acknowledging that the optimal duration is unknown [2].

GLP-1 drugs are proven to damage teeth

The evidence reviewed does not establish direct dental toxicity. Reflux and repeated vomiting are independently associated with dental erosion, and those gastrointestinal effects can occur during treatment [3] [5] [6]. Those are different claims.

Dry mouth is a proven class effect

The published semaglutide evidence in this source set is a three-patient case series [7]. That is a clinical signal, not evidence of a predictable effect across a drug class.

Bottom line

Yes, your dentist should know you take a GLP-1 medication, and as of 2026 the ADA's own health history form asks [1].

For routine dental care, the sources reviewed do not establish a general rule requiring anyone to interrupt GLP-1 therapy because they have a dental appointment.

The issue becomes more important when general anesthesia or deep sedation is planned. Current Wegovy and Mounjaro labeling states that these medicines delay gastric emptying and carries warnings about rare postmarketing aspiration reports during such procedures [3] [4]. Current guidance is risk-based rather than uniform [2].

Vomiting and reflux are worth mentioning too, because repeated gastric exposure is independently associated with dental erosion [5] [6].

What the evidence does not establish is equally important. It does not show that GLP-1 medications universally cause tooth decay, gum disease, dental erosion, or dry mouth.

Tell your dentist what you take. Tell them what symptoms you are having. Do not stop the medication on your own.

Primary sources

1. American Dental Association. Medical/Dental Health History. Practice management resource, last updated March 2026. States that the Council on Dental Practice updated the Medical/Dental Health History Form to include GLP-1 medications in the current medication list and a mental health prompt, and sets out the requirements for maintaining, reviewing, and updating patient health histories. Related ADA News reporting dated March 2026 records that the Council approved the changes in January 2026, that the updated forms became available on March 24, and that the forms were last revised in 2021.
2. Kindel TL, Wang AY, Wadhwa A, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgical Endoscopy. 2025;39(1):180-183. Published online October 29, 2024. DOI 10.1007/s00464-024-11263-2. Published concurrently in Clinical Gastroenterology and Hepatology and Surgery for Obesity and Related Diseases.
3. Novo Nordisk. WEGOVY (semaglutide) injection, for subcutaneous use. FDA-approved prescribing information, current version carrying a June 2026 revision. Establishes delayed gastric emptying, the pulmonary aspiration warning during general anesthesia or deep sedation, the statement that available data are insufficient to inform mitigation, patient disclosure instructions, and gastrointestinal adverse reactions including vomiting and gastroesophageal reflux disease.
4. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. FDA-approved prescribing information. Establishes delayed gastric emptying and the pulmonary aspiration warning during general anesthesia or deep sedation.
5. Holbrook WP, Furuholm J, Gudmundsson K, Theodors A, Meurman JH. Gastric reflux is a significant causative factor of tooth erosion. Journal of Dental Research. 2009;88(5):422-426. DOI 10.1177/0022034509336530.
6. Uhlen MM, Tveit AB, Stenhagen KR, Mulic A. Self-induced vomiting and dental erosion: a clinical study. BMC Oral Health. 2014;14:92. DOI 10.1186/1472-6831-14-92.
7. Mawardi HH, Almazrooa SA, Dakhil SA, et al. Semaglutide-associated hyposalivation: A report of case series. Medicine (Baltimore). 2023;102(52):e36730. DOI 10.1097/MD.0000000000036730.

This article provides general health information and is not individualized medical or dental advice. Medication decisions before a procedure should be made with the clinicians responsible for your treatment.